drugset
drugset / Trial / NCT00466726

Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

NCT00466726 ↗

Phase 2 Completed 57 enrolled GIMEMA Foundation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Timeline

Start
2007-03
Primary completion
2014-07
Completion
2014-07

Publications

  • Results BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Drugs

EvaluationDrugModalityDoseRoute
Subject CMLVAX100 Vaccine — Subcutaneous
Background sargramostim Protein / enzyme biologic — Subcutaneous

Indications

leukemia